PATIENT ACCESS WORLD CONGRESS 2025 EUROPE
Improving Patient Access for Better Health Outcomes and Quality of Life
London, UK, London, United Kingdom
Day 2 - Tuesday 21st October 2025
CHALLENGES & OPPORTUNITIES
- Understand the cause of health inequalities and how they affect the community
- Causes of health inequalities
- How do health inequalities impact health and wellbeing?
- How companies can address health equity through people and patient engagement;
- Success measures of efforts to advance health equity
- What can the industry do to promote health equity in the future?
Moderator:
Panelists:
- An introduction to the Access to Medicine Foundation and what we do (as we understand not everyone may be familiar with us).
- A discussion on the decreasing focus on R&D for diseases that affect LMICs and how pharma pipelines have changed over the last decade and what this means for access.
- Key insights from the 2024 Access to Medicine Index on clinical trials and access planning.
- Practical examples and recommendations on how companies can help close these gaps in access.
Sjors van Gijzel, Researcher, Access to Medicines Foundation
- Presentation of a mixed-method study findings
- How to use the findings with a range of different stakeholders
- Learnings from the initiative and next steps
Victoria Hayes, Director Public Affairs, Northern Cluster, Kyowa Kirin
- Discover how telehealth can make healthcare more accessible
- Understanding patient perspectives on telemedicine crucial for its adoption and efficacy.
- Key recommendations for telemedicine optimization and equity
- Continuous evaluation and adaptation essential to address technological challenges and disparities in telehealth usage
- Using artificial intelligence (AI) to address barriers to Patient Access
- How can data and AI be utilised to promote access?
- How can AI tools make it easier and more affordable for patients to receive needed care?
- Potential to revolutionise the healthcare industry further
- Importance of early consideration and integration of RWE into market access and commercialization strategies
- How and where to access real-world Data?
- Leveraging existing data sources and technologies to enhance study quality and streamline processes
- Robust planning and interpretation methods for effective utilisation of data for driving evidence-based decision making
- Addressing the shifting regulations
- Payer revenue optimization strategies
- The need for a 360-degree perspective across the drug development life cycle,
- The promise of real-world data (RWD) to address complex challenges
Bob Stevens, Group CEO, MPS SOCIETY
- Encourage shared decision-making to help patients feel more empowered and make informed choices.
- Open and clear communication between patients and providers to build trust and understanding.
- Educate patients to ensure patients understand their treatment plan, medications, and diagnosis
- Use innovative technology to improve the patient experience
Katherine Taylor, Patient Advocacy Lead, Pfizer UK
- Recommendations to enhance value assessment and recognition
- Strategies to improve implementation
Optimising the benefits of value-based pricing, through complementary tools
- Understanding the intricacies of pharma reimbursement
- Reimbursement hurdles that impact market access of launching new therapies and patient access
- The impact of Health Technology Assessment in reimbursement
- A successful pharma reimbursement strategy
- Future trends in reimbursement
- Addressing the unequal access to medicines for patients across Europe
- Disparities in the time it takes for European patients to access new medicines persist
- Factors causing delays and barriers to access
- Stakeholders collaboration towards pragmatic solutions that work for patients and help address Europe’s health inequalities.
Moderator:
Panelists:
- Robust market access strategy to help ensure that pharmaceutical innovations benefit the widest population possible
- Rigorous, proactive methodologies to support reimbursement
- Effective approach guided by patient-centricity to ensure patients receive timely treatment.
- Continuous medical education resulting in better clinical outcomes for patients and improved physician performance
Moderator:
Beverly Lui, Head, Patient Advocacy and Engagement International Region, Apellis
Panelists: